P-cadherin antibodies

Provided is an isolated antibody or antigen-binding portion thereof that binds to P-cadherin and comprises a VH domain and a VL domain, wherein the VH domain comprises: a) a VH CDR1, b) a VH CDR2, and c) a VH CDR3, and wherein the VL domain comprises: d) a VL CDR1, e) a VL CDR2 and f) a VL CDR3, all...

Full description

Saved in:
Bibliographic Details
Main Authors BOURNER, MAUREEN JERI, HEAD, RICHARD DAVID, MINTER, RALPH RAYMOND, BAUER, CHRISTOPHER TODD, JOY, WILLIAM DEAN, BOYLE, MELANIE, MOFFAT, MARK ALLEN, GRIGGS, DAVID WILLIAM, MAZZARELLA, RICHARD ALLEN, THIELE, BARRETT RICHARD, VANARSDALE, TODD LEE, CASPERSON, GERALD FRIES
Format Patent
LanguageEnglish
Published 25.09.2009
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided is an isolated antibody or antigen-binding portion thereof that binds to P-cadherin and comprises a VH domain and a VL domain, wherein the VH domain comprises: a) a VH CDR1, b) a VH CDR2, and c) a VH CDR3, and wherein the VL domain comprises: d) a VL CDR1, e) a VL CDR2 and f) a VL CDR3, all with specified sequences or variants differing only by 1 or 2 conservative amino acid substitutions. Further provided are corresponding nucleic acid molecules encoding said antibodies, with specified sequences.
Bibliography:Application Number: NZ20060562234